Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL788979 | 0.91 | FASN (0.48) | FASN | |
| SCHEMBL15081809 | 0.89 | FASN (0.50) | FASN | |
| SCHEMBL806540 | 0.88 | FASN (0.49) | FASNCYP2C9 | |
| SCHEMBL806569 | 0.88 | FASN (0.51) | FASN | |
| SCHEMBL12474445 | 0.88 | FASN (0.51) | FASN | |
| SCHEMBL15064385 | 0.87 | FASN (0.48) | FASN | |
| SCHEMBL788926 | 0.85 | FASN (0.66) | FASN | |
| SCHEMBL789379 | 0.85 | FASN (0.48) | FASN | |
| SCHEMBL806545 | 0.84 | FASN (0.54) | FASN | |
| SCHEMBL10231146 | 0.83 | FASN (0.49) | FASN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130172384-A1 | FATTY ACID SYNTHASE INHIBITORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED | 2013-07-04 | — | — | US | claimed |
| EP-2616071-A2 | FATTY ACID SYNTHASE INHIBITORS | GlaxoSmithKline Intellectual Property Development Limited (GB) | 2013-07-24 | — | — | EP | disclosed |
| US-20130172384-A1 | FATTY ACID SYNTHASE INHIBITORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED | 2013-07-04 | — | — | US | disclosed |
| US-20130172384-A1 | FATTY ACID SYNTHASE INHIBITORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED | 2013-07-04 | — | — | US | disclosed |
| US-20130172384-A1 | FATTY ACID SYNTHASE INHIBITORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED | 2013-07-04 | — | — | US | disclosed |
| WO-2012037299-A2 | FATTY ACID SYNTHASE INHIBITORS | GLAXOSMITHKLINE LLC (US) | 2012-03-22 | — | — | WO | disclosed |
| WO-2012037299-A2 | FATTY ACID SYNTHASE INHIBITORS | GLAXOSMITHKLINE LLC (US) | 2012-03-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130172384-A1 | FATTY ACID SYNTHASE INHIBITORS | FASN, FADS1, FADS2 | FASN 1/4885CYP2C9 769/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.